In vitro activity and efficacy of novel dual PARP-HDAC inhibitors

被引：0
|
作者：
Truong, Sarah
Ghaidi, Fariba
Ramos, Louise
Joshi, Jay
Brown, Dennis
Sankar, Neil
Langlands, John
Bacha, Jeffrey
Shen, Wang
Daugaard, Mads
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P081
引用
收藏
页数：2
相关论文
共 50 条
  • [1] In vitro efficacy of a novel dual PARP-HDAC inhibitor in ewing sarcoma
    Truong, Sarah
    Zhai, Beibei
    Ghaidi, Fariba
    Ramos, Louise
    Joshi, Jay
    Brown, Dennis
    Sankar, Neil
    Langlands, John
    Bacha, Jeffrey
    Shen, Wang
    Sorensen, Poul
    Daugaard, Mads
    CLINICAL CANCER RESEARCH, 2022, 28 (18)
  • [2] A novel dual PARP-HDAC inhibitor for treatment of Ewing sarcoma
    Truong, S.
    Zhai, B.
    Ghaidi, F.
    Ramos, L.
    Joshi, J.
    Brown, D.
    Sankar, N.
    Langlands, J.
    Bacha, J.
    Shen, W.
    Sorensen, P.
    Daugaard, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S39 - S39
  • [3] A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
    Ramos, Louise
    Truong, Sarah
    Zhai, Beibei
    Joshi, Jay
    Ghaidi, Fariba
    Lizardo, Michael M.
    Shyp, Taras
    Kung, Sonia H. Y.
    Rezakhanlou, Alireza M.
    Oo, Htoo Zarni
    Adomat, Hans
    Le Bihan, Stephane
    Collins, Colin
    Bacha, Jeffrey
    Brown, Dennis
    Langlands, John
    Shen, Wang
    Lallous, Nada
    Sorensen, Poul H.
    Daugaard, Mads
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3541 - 3553
  • [4] Design, synthesis and antitumor activity study of PARP-1/HDAC dual targeting inhibitors
    Chi, Ziwei
    Bai, Ying
    Li, Jing
    Wang, Kewei
    Xu, Yungen
    Luan, Yepeng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 71
  • [5] Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity
    Mackwitz, Marcel K. W.
    Hesping, Eva
    Eribez, Korina
    Schoeler, Andrea
    Antonova-Koch, Yevgeniya
    Held, Jana
    Winzeler, Elizabeth A.
    Andrews, Katherine T.
    Hansen, Finn K.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 211
  • [6] Antitumor activity of novel POLA1-HDAC11 dual inhibitors
    Dallavalle, Sabrina
    Musso, Loana
    Cincinelli, Raffaella
    Darwiche, Nadine
    Gervasoni, Silvia
    Vistoli, Giulio
    Guglielmi, Mario B.
    Pizzulo, Maddalena
    Modica, Elisa
    Prosperi, Federica
    Signorino, Giacomo
    Colelli, Fabiana
    Cardile, Francesco
    Fucci, Alessandra
    Riccio, Assunta
    Pisano, Claudio
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 228
  • [7] Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
    Yuan, Zigao
    Chen, Shaopeng
    Sun, Qinsheng
    Wang, Ning
    Li, Dan
    Miao, Shuangshuang
    Gao, Chunmei
    Chen, Yuzong
    Tan, Chunyan
    Jiang, Yuyang
    BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (15) : 4100 - 4109
  • [8] Novel PARP1 inhibitors potentiate doxorubicin antitumor activity in vitro
    Rakitina, Tatiana V.
    Zeifman, Alexey A.
    Novikov, Fedor N.
    Stroganov, Oleg V.
    Stroylov, Victor S.
    Svitanko, Igor V.
    Frank-Kamenetskii, Anastasia
    Chilov, Ghermes G.
    MENDELEEV COMMUNICATIONS, 2015, 25 (05) : 364 - 366
  • [9] Novel cinnamohydroxamic acid derivatives as HDAC inhibitors with anticancer activity in vitro and in vivo
    Wang, Lihui
    Bao, Xuefei
    Yang, Jingyu
    Li, Huahuan
    Zhou, Qifan
    Jiang, Xiaorui
    Li, Meng
    Liu, Xing
    Yuan, Xiangzhong
    Sun, Yuhong
    Chen, Junli
    Zhang, Jingyuan
    Chen, Guoliang
    Wu, Chunfu
    CHEMICO-BIOLOGICAL INTERACTIONS, 2016, 249 : 64 - 70
  • [10] A novel approach to assess the efficacy of HDAC inhibitors in vivo
    Soner, Altiok
    Gemmer, Jennifer
    Brazelle, William
    Haura, Eric
    CANCER RESEARCH, 2009, 69
12345